<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887653</url>
  </required_header>
  <id_info>
    <org_study_id>2007-09</org_study_id>
    <nct_id>NCT00887653</nct_id>
  </id_info>
  <brief_title>Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy</brief_title>
  <official_title>Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-infected Patients With Hyperlipidemia While on Current Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Miriam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Miriam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The success of combination antiretroviral therapy heralded a revolution in the treatment of
      HIV in the mid-1990s. However, severe treatment-associated side effects have been observed
      including diabetes and increased cholesterol which are linked to premature heart attacks.
      This effect has been described among many regimens containing protease inhibitors (PIs), as
      well as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Raltegravir is a new
      medicine which has been shown to be potent and efficacious in suppression of the HIV. This
      study hopes to determine if switching from a PI or NNRTI to raltegravir will decrease
      cholesterol in subjects with high cholesterol and well controlled HIV. In addition, the study
      aims to confirm that raltegravir is safe and well tolerated. It also seeks to confirm if
      raltegravir will have similar anti-HIV activity compared with the patient's previous regimen.

      The study will last 6 months and will involve 20 subjects. HIV-1 infected men and women on
      PIs or NNRTIs for at least 12 months before study entry with well controlled HIV will be
      recruited.

      Hypotheses:

        1. Patients with elevated lipid levels while on combination antiretroviral therapy with PIs
           or NNRTIs will experience an improvement in lipid levels after switching their PI or
           NNRTI to a raltegravir based regimen.

        2. Raltegravir will be safe and well tolerated.

        3. Raltegravir will have similar antiretroviral activity compared with the prior regimen.

      Primary Objective:

      To demonstrate an improvement in lipid profile (triglycerides or LDL) in subjects switched to
      raltegravir from PIs or NNRTIs at 2, 3, and 6 months after study entry.

      Study Design: Subjects will be given the option to switch from their current regimen to
      raltegravir at 400mg twice daily. Those who consent, will receive raltegravir provided by the
      study for 6 months. At entry, the subjects will undergo a complete physical exam and
      thereafter targeted exams at each visit. Labs will be drawn as part of clinical care at 2, 3,
      and 6 months. Some of the blood will be stored for later analysis. Also, the subjects will
      answer regular surveys on drug toxicity and quality of life. Their cholesterol level will be
      compared before and after the study. At the end of the study, the participants may choose to
      continue on raltegravir if they desire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success of combination antiretroviral therapy heralded a revolution in the management of
      patients with HIV in the mid-1990s. Increasingly, severe treatment-associated metabolic side
      effects have been observed and linked to premature coronary artery disease. This effect has
      been described among many regimens containing protease inhibitors (PIs) as well as
      non-nucleoside reverse transcriptase inhibitors (NNRTIs).

      Raltegravir is a novel HIV-1 integrase inhibitor which in a comparison study with efavirenz
      has been shown to be potent and efficacious in suppression of the HIV-1. Minimal side effects
      were reported which mainly included nausea, headache, dizziness, diarrhea, and insomnia.

      Hypotheses:

        1. Patients with elevated lipid levels while on combination antiretroviral therapy with PIs
           or NNRTIs will experience an improvement in lipid levels after switching their PI or
           NNRTI to a raltegravir based regimen.

        2. Raltegravir will be safe and well tolerated.

        3. Raltegravir will have similar antiretroviral activity compared with the prior regimen.

      Primary Objective:

      To demonstrate an improvement in triglycerides or LDL in subjects switched to raltegravir
      from PIs or NNRTIs at 2 months, 3 months, and 6 months after study entry.

      Secondary Objectives:

      To assess the immunologic and virologic outcomes in subjects switched to raltegravir from PIs
      or NNRTIs at 2, 3, and 6 months after entry.

      Study Design:

      This will be a single arm study where subjects will be given the option to switch from their
      current regimen to raltegravir at 400mg twice daily.

      Primary endpoint: Change from baseline LDL and change from baseline triglycerides at 3
      months, adjusted for BMI and smoking status.

      The subjects' plasma viral load before and after switching will be compared with a paired t
      test at each time point.

      The subjects' CD4+ T cell count will be compared with a paired t test before and after
      switching.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Assess changes from baseline triglycerides at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Triglycerides</measure>
    <time_frame>6 months</time_frame>
    <description>Assess changes from baseline triglycerides at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Plasma Viral Load Below the Limit of Detection</measure>
    <time_frame>6 months</time_frame>
    <description>Assess proportion of patients with PVL below limit of detection at end of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18

          -  Fasting LDL&gt;130 mg/dL

          -  Fasting triglycerides &gt;250 mg/dL

          -  Plasma viral load below 50 copies/mL on current regimen for 6 months prior to study
             entry.

          -  No prior history of any NRTI resistance.

        Exclusion Criteria:

          -  History of NRTI resistance mutations

          -  Need for medications that have drug interactions with raltegravir: dilantin,
             phenobarbitol and rifampin

          -  Unstable clinical condition, such as unstable cardiac disease, or cancer requiring
             ongoing chemotherapy or radiation therapy, or other medical condition which, in the
             opinion of the investigator, would preclude a subject from safely undergoing study
             procedures.

          -  Breast-feeding or pregnancy.

          -  Use of immunosuppressive medications within 60 days prior to study entry.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Tashima, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Miriam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital Immunology Clinic</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>September 19, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2014</results_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Miriam Hospital</investigator_affiliation>
    <investigator_full_name>Aadia Rana</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir Arm</title>
          <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir Arm</title>
          <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="40" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Triglycerides</title>
        <description>Assess changes from baseline triglycerides at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Arm</title>
            <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Triglycerides</title>
          <description>Assess changes from baseline triglycerides at 3 months</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="93" upper_limit="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Plasma Viral Load Below the Limit of Detection</title>
        <description>Assess proportion of patients with PVL below limit of detection at end of study.</description>
        <time_frame>6 months</time_frame>
        <population>One subject was prematurely discontinued from the study at week 12 due to detectable HIV-1 RNA of 57 copies/mL that was sustained at 61 copies on repeated measurement two weeks later.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Arm</title>
            <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Plasma Viral Load Below the Limit of Detection</title>
          <description>Assess proportion of patients with PVL below limit of detection at end of study.</description>
          <population>One subject was prematurely discontinued from the study at week 12 due to detectable HIV-1 RNA of 57 copies/mL that was sustained at 61 copies on repeated measurement two weeks later.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Triglycerides</title>
        <description>Assess changes from baseline triglycerides at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Arm</title>
            <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Triglycerides</title>
          <description>Assess changes from baseline triglycerides at 6 months</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="93.3" upper_limit="170.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir Arm</title>
          <description>This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
raltegravir: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Virologic Failure</sub_title>
                <description>One subject was found at week 12 with HIV-1 RNA of 57 copies/mL; repeat with 61 copies. Genotype revealed no evidence of resistance. The subject was then initiated on darunavir/ritonavir regimen with subsequent re-suppression to &lt;50 copies/mL.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aadia Rana</name_or_title>
      <organization>THE MIRIAM HOSPITAL</organization>
      <phone>4017934680</phone>
      <email>arana@lifespan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

